ArticleHarm reduction journal2025
Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the United States, only 15-20% of people with opioid use disorder (OUD) receive medications for OUD annually. Injectable opioid agonist treatment with hydromorphone (iOAT-H) is a novel approach that reduces non-prescribed opioid use. However, interest in iOAT-H among women, who face unique challenges in OUD treatment, may be different than men. This study evaluates women's attitudes toward iOAT-H, and gender disparities in OUD-related risks, exploring potential gender-specific treatment needs. We hypothesized that women would be less interested in iOAT-H than men given the disproportionate stigma women face in accessing OUD treatment.
methodsThis is a secondary analysis of a cross-sectional study of urban syringe service program participants. Participants self-reported interest in iOAT-H, which was assessed on a 4-point scale with 3 or 4 considered "interested." Participants also provided self-reported data on preferences for OUD treatment and their OUD-related risks, including frequency of drug use and injection practices. Descriptive statistics and comparative analyses were employed to explore gender differences.
resultsOf 108 participants, 31% were women and 69% were men with a mean age of 43.0 (SD ± 10.8). Almost all participants had severe OUD (98.1%) and had prior OUD care (96.3%). Most women (68%) and men (64%) reported interest in iOAT-H. For OUD treatment preferences, most women chose iOAT-H (56%), while men most commonly endorsed methadone treatment (42%) as their preferred option. Women had more OUD-related risks than men including injecting more times per day (5 vs. 3, p > 0.01) and injecting in public more often (24 vs. 7, p = 0.05) in the past 30 days.
conclusionInterest in iOAT-H was high among women and men, but we found gender differences in OUD-related risks. This may reflect unmet needs among women who would potentially enter treatment with iOAT-H, but additional work is necessary to examine specific risks such as mental health, trauma exposure, and creating safe treatment spaces for women. Nonetheless, iOAT-H appeared acceptable to women in our sample, and many treatment-experienced people who inject drugs would prefer iOAT-H to other available OUD treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.